



22 May 2019
Australian Securities Exchange Announcement

Update on the development of a Personalised Genetic Test for Predicting Remission of Depression Symptoms when Using Main Psychotropic Drugs

- Evaluating an individual's likelihood to remit from depression given one's brain genetic profile - 80% Accuracy achieved
- Genetic test based on analysis of over 1,000 patients with depression
- Increases monetisation potential for legacy iSpot asset of Total Brain

Total Brain (ASX: TTB), sponsor of the iSPOT-D study (International Study to Predict Optimised Treatment in Depression), has developed an objective Personalised Medicine Test to determine who is more and less likely to respond to three of the most common antidepressant medications. The test is based on a clinical and genetic analysis of over 1,000 patients' antidepressant drug response rates and combines the previous iSPOT-D study results and the recently concluded genetic analysis of 850,000 SNPs by Total Brain.

A whitepaper detailing the methodology and results of the study can be found here: <https://bit.ly/2ZrsNS8>

While the strategic plan of the company is focused on servicing the the B2B Corporate and B2C Affinity markets for the Total Brain digital product, the Company views this latest genetic screening result as a positive development for the business and its shareholders. Although the final scientific validity of the genetic test is subject to the results of a full replication of the study, the results help support the value potential of the iSpot assets. Total Brain continues to work with a New York-based investment bank in evaluating its strategic alternatives for iSpot, including finding a commercialisation partner who would work to successfully replicate the findings of the genetic test conducted in 2018 by Total Brain before subsequently monetising it.

Major Depressive Disorder is one of the most common psychiatric disorders in the US, with over 15 million people impacted and costing \$100 billion annually, of which less than half achieve symptom remission with the first medication tried. Primary Care Physicians (PCPs), Psychiatrists and other clinicians face daily challenges of objective decision making for treatment options in Depression.

"The development of this test represents a major step forward in the treatment of depression, and underscores the enormous value of the world's largest neuroscientific database that powers the Total Brain platform." Louis Gagnon, CEO of Total Brain, said.

About Total Brain Limited (ASX: TTB)

Total Brain Limited (TTB) is a San Francisco and Sydney based company that has developed and sells Total Brain, the world's first mental health and fitness platform powered by the largest standardized brain database and has over 600,000 registered users. Its SaaS platform helps people scientifically measure and optimize their brain capacities while managing the risk of common mental conditions. Benefits for employers and payers across the United States include productivity improvement and healthcare cost reduction. For more information, please visit www.totalbrain.com and follow us on [Twitter](#), [LinkedIn](#) and [Facebook](#).

Investor

Matt Morgan
Director
M: +61 408 019 458
E: ir@totalbrain.com

Media

Nigel Kassulke
Canning Corporate Communications
M: +61 (0) 407 904 874
E: nkassulke@cannings.net.au